DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

DexCom, Inc.

DexCom (DXCM) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.
The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.
The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.
As such, the Zacks rating upgrade for DexCom is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.
Most Powerful Force Impacting Stock Prices
The change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.
For DexCom, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.
Harnessing the Power of Earnings Estimate Revisions
Empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .
Earnings Estimate Revisions for DexCom
For the fiscal year ending December 2025, this medical device company is expected to earn $2.03 per share, which is unchanged compared with the year-ago reported number.
Analysts have been steadily raising their estimates for DexCom. Over the past three months, the Zacks Consensus Estimate for the company has increased 0.2%.
Bottom Line
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
The upgrade of DexCom to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include
Stock #1: A Disruptive Force with Notable Growth and Resilience
Stock #2: Bullish Signs Signaling to Buy the Dip
Stock #3: One of the Most Compelling Investments in the Market
Stock #4: Leader In a Red-Hot Industry Poised for Growth
Stock #5: Modern Omni-Channel Platform Coiled to Spring
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.
Download Atomic Opportunity: Nuclear Energy's Comeback free today.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

DexCom (DXCM) Upgraded to Strong Buy: Here's What You Should Know

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Nuveen Growth Opportunities ETF (Symbol: NUGO) where we have detected an approximate $174.6 million dollar outflow -- that's a 6.0% decrease week over week (from 80,150,000 to 75,350,000). Among the largest underlying components of NUGO, in trading today Corteva Inc (Symbol: CTVA) is up about 0.2%, AutoZone, Inc. (Symbol: AZO) is up about 0.8%, and DexCom Inc (Symbol: DXCM) is higher by about 2%. For a complete list of holdings, visit the NUGO Holdings page » The chart below shows the one year price performance of NUGO, versus its 200 day moving average:
Looking at the chart above, NUGO's low point in its 52 week range is $26.10 per share, with $36.58 as the 52 week high point — that compares with a last trade of $36.36. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Free Report: Top 8%+ Dividends (paid monthly)
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Top Ten Hedge Funds Holding AEM
NVR Average Annual Return
BBVA Price Target
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

NUGO, CTVA, AZO, DXCM: Large Outflows Detected at ETF

The S&P 500 Index ($SPX) (SPY) Tuesday closed down -0.11%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +0.91%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.89%. September E-mini S&P futures (ESU25) are down -0.12%, and September E-mini Nasdaq futures (NQU25) are down -0.91%.
Stock indexes on Tuesday settled mixed, with the Dow Jones Industrials posting a 4-1/2 month high. The S&P 500 and Nasdaq 100 moved lower Tuesday and consolidated below Monday’s all-time highs. Tesla closed down more than -5% to lead technology stocks lower and weigh on the overall market after President Trump threatened to withdraw subsidies from Elon Musk’s companies in response to Musk’s criticism of the Republican reconciliation bill. The markets are also monitoring progress on trade talks ahead of President Trump’s July 9 deadline, as well as congressional wrangling over the passage of President Trump’s tax and spending bill.
Join 200K+ Subscribers: Find out why the midday Barchart Brief newsletter is a must-read for thousands daily.
The Senate passed the Republican reconciliation bill on Tuesday by a 51-50 vote. The bill now goes to the House, where it will be voted on sometime this week. Speaker Johnson said the House “will work quickly” to pass the bill by July 4. The reconciliation bill has the debt ceiling hike that is necessary to avert a Treasury default when the Treasury runs out of borrowing authority sometime between mid-August and late September. The dollar index fell to a 3-1/3 year low Tuesday as the nonpartisan Congressional Budget Office estimates that the bill would add nearly $3.3 trillion to US budget deficits over the next decade.
Stocks remained lower Tuesday after the better-than-expected US ISM and JOLTS reports pushed bond yields higher and dampened expectations of imminent Fed rate cuts. Also, Fed Chair Powell reiterated his wait-and-see stance on interest rates as he expects tariffs to show up in inflation data over the coming months.
The US June ISM manufacturing index rose +0.5 to 49.0, stronger than expectations of 48.8. Also, the June ISM prices paid sub-index rose +0.3 to 69.7, stronger than expectations of 69.5.
US May JOLTS job openings unexpectedly rose +374,000 to a 6-month high of 7.769 million, showing a stronger labor market than expectations of a decline to 7.300 million.
Fed Chair Powell said he expects the impacts of tariffs to show up in inflation data over the coming months, but the impact could be “higher or lower, or later or sooner than we expected.”
Better-than-expected manufacturing news from China is supportive of global economic growth prospects. The China June Caixin manufacturing PMI rose +2.1 to 50.4, stronger than expectations of 49.3.
On the negative side for stocks is the upcoming earnings season, which begins next week. Bloomberg Intelligence data show that the consensus for Q2 earnings of S&P 500 companies is for a rise of +2.8% year-over-year, the smallest increase in two years. Also, only six of the 11 S&P 500 sectors are projected to post an increase in earnings, the fewest since Q1 of 2023, according to Yardeni Research.
During this holiday-shortened week, the markets will look for additional trade and tariff news along with progress in the passage of President Trump’s tax bill. On Wednesday, the June ADP employment change is expected to rise by +90,000. On Thursday, Jun nonfarm payrolls are expected to climb by +113,000, and the June employment rate is expected to tick up +0.1 to 4.3%. Also, June average hourly earnings are expected to rise +0.3% m/m and +3.8% y/y. In addition, weekly initial unemployment claims are expected to climb +5,000 to 241,000, and May factory orders are expected to jump +8.1% m/m. Finally, the Jun ISM services index is expected to climb +0.7 to 50.6.
Federal funds futures prices are discounting the chances at 21% for a -25 bp rate cut at the July 29-30 FOMC meeting.
Overseas stock markets on Tuesday settled mixed. The Euro Stoxx 50 closed down -0.39%. China’s Shanghai Composite closed up +0.39%. Japan’s Nikkei Stock 225 closed down -1.24%.
Interest Rates
September 10-year T-notes (ZNU25) Tuesday closed down by -8.5 ticks. The 10-year T-note yield rose +2.0 bp to 4.248%. Sep T-notes fell from a 2-month high Tuesday and turned lower, and the 10-year T-note yield rebounded from a 2-month low of 4.185% and turned higher.
Speculation that Congress is close to passing President Trump’s tax and spending bill has sparked some weakness in T-note prices. The Congressional Budget Office estimates that the bill would add nearly $3.3 trillion to US deficits over the next decade, which would boost Treasury security sales to fund the deficits. Losses in T-notes accelerated Tuesday after the stronger-than-expected ISM and JOLTS reports were hawkish for Fed policy.
T-note prices initially moved higher on Tuesday due to carryover support from strength in European government bonds. T-notes were also boosted as positive trade news has bolstered hopes for smaller-than-expected tariffs, which would soften the inflation outlook.
European government bond yields on Tuesday moved lower. The 10-year German bund yield fell -3.3 bp to 2.574%. The 10-year UK gilt yield dropped to an 8-week low of 4.417% and finished down -3.5 bp to 4.454%.
The Eurozone June CPI edged up to +2.0% y/y from +1.9% y/y in May, right on expectations. The June core CPI was unchanged from May at +2.3% y/y, right on expectations.
The ECB May 1-year CPI inflation expectations unexpectedly eased to +2.8% from +3.1% in Apr, versus expectations of no change at +3.1%. The May 3-year CPI expectations unexpectedly eased to +2.4% from +2.5% in Apr versus expectations of no change at +2.5%.
The Eurozone June manufacturing PMI was revised upward by +0.1 to 49.5 from the previously reported 49.4.
The German June unemployment change rose +11,000, showing a stronger labor market than expectations of +15,000. The Jun unemployment rate was unchanged at 6.3%, showing a stronger labor market than expectations of an increase to 6.4%.
ECB Governing Council member Kazaks said, “If the euro were to significantly appreciate further, it could weigh down on inflation and exports, which could tilt the balance toward another ECB interest rate cut.”
Swaps are discounting the chances at 6% for a -25 bp rate cut by the ECB at the July 24 policy meeting.
US Stock Movers
Tesla (TSLA) closed down more than -5% as President Trump threatened to withdraw government subsidies from Elon Musk’s companies after Musk criticized the Republicans’ reconciliation bill. Analysts estimate that changes to regulatory credits could threaten up to 40% of Tesla’s profits.
Weakness in chip stocks is a negative factor for the overall market. Advanced Micro Devices (AMD) closed down more than -4%, and Broadcom (AVGO) and ARM Holdings Plc (ARM) closed down more than -3%. Also, Nvidia (NVDA) closed down more than -2% to lead losers in the Dow Jones Industrials. In addition, Marvell Technology (MRVL), Micron Technology (MU), and ASML Holding NV (ASML) closed down more than -1%.
Makers of glucose monitors and insulin pumps retreated Tuesday after the US government proposed a payment scheduling change for diabetes devices as well as a competitive bidding program. As a result, Tandem Diabetes Care (TNDM) closed down more than -7%, and Insulet (PODD) and Dexcom (DXCM) closed down more than -4%.
Warner Bros Discovery (WBD) closed down more than -4% after holder Advance/Newhouse planned to sell as much as $1.1 billion of its holdings in WBD via an overnight unregistered block trade.
AeroVironment (AVAV) closed down more than -11% after announcing plans to sell $750 million worth of shares of its common stock in an underwritten public offering and $600 million of aggregate convertible senior notes due 2020.
Dyne Therapeutics (DYN) closed down more than -8% after offering 24.2 million shares of its common stock in an underwritten public offering at a price of $8.25 per share, below Monday’s closing price of $9.52.
Sweetgreen Inc (SG) closed down more than -2% after TD Cowen downgraded the stock to hold from buy.
US-listed Macau casino operators rallied Tuesday after Macau’s monthly gaming revenue rose +19% y/y in June, above expectations of a +9.4% y/y gain. As a result, Las Vegas Sands (LVS) closed up more than +8% to lead gainers in the S&P 500. Also, Wynn Resorts Ltd. (WYNN) closed up more than +8% and MGM Resorts International (MGM) closed up more than +7%.
Packaging Corporation of America (PKG) closed up more than +7% after the company acquired Greif Containerboard for $1.8 billion, and Barclays said the purchase will increase PKG’s capacity to 6.0 MMT, holding its place as the third-largest containerboard maker in the US.
Ryder System (R) closed up more than +6% after Wolfe Research upgraded the stock to outperform from peer perform with a price target of $183.
Hasbro (HAS) closed up more than +4% after Goldman Sachs upgraded the stock to buy from neutral with a price target of $85.
Nike (NKE) closed up more than +3% after Argus Research upgraded the stock to buy from hold with a price target of $85.
CH Robinson Worldwide (CHRW) closed up more than +2% after Wolfe Research upgraded the stock to outperform from peer perform with a price target of $112.
Trade Desk (TTD) closed up more than +2% after Citibank raised its price target on the stock to $90 from $82.
Earnings Reports (7/2/2025)
Franklin Covey Co (FC), UniFirst Corp/MA (UNF).
On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Stocks Settled Mixed as Higher Bond Yields Weigh on Sentiment

Sadie Stern, the EVP of $DXCM, sold 1,466 shares of the company on 06-26-2025 for an estimated $124,697. We received data on the trade from a recent SEC filing. This was a sale of approximately 1.3% of their shares of this class of stock. Following this trade, they now own 108,155 shares of this class of $DXCM stock.
$DXCM Insider Trading Activity
$DXCM insiders have traded $DXCM stock on the open market 21 times in the past 6 months. Of those trades, 0 have been purchases and 21 have been sales.
Here’s a breakdown of recent trading of $DXCM stock by insiders over the last 6 months:
KEVIN R SAYER (Chairman, CEO & President) has made 0 purchases and 2 sales selling 65,857 shares for an estimated $5,186,579.
MICHAEL JON BROWN (EVP, Chief Legal Officer) has made 0 purchases and 3 sales selling 23,500 shares for an estimated $1,799,190.
SADIE STERN (EVP, Chief HR Officer) has made 0 purchases and 4 sales selling 20,919 shares for an estimated $1,619,495.
JEREME M SYLVAIN (EVP, Chief Financal Officer) has made 0 purchases and 5 sales selling 21,091 shares for an estimated $1,543,112.
JACOB STEVEN LEACH (EVP, Chief Operating Officer) has made 0 purchases and 2 sales selling 16,710 shares for an estimated $1,219,602.
NICHOLAS AUGUSTINOS has made 0 purchases and 2 sales selling 6,290 shares for an estimated $517,906.
MARK G FOLETTA sold 2,750 shares for an estimated $228,604
MATTHEW VINCENT DOLAN (EVP, Strategy & Corporate Dev) sold 1,183 shares for an estimated $102,819
BRIDGETTE P HELLER sold 352 shares for an estimated $24,756
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$DXCM Hedge Fund Activity
We have seen 480 institutional investors add shares of $DXCM stock to their portfolio, and 504 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 2,925,241 shares (+40.6%) to their portfolio in Q1 2025, for an estimated $199,764,707
JENNISON ASSOCIATES LLC added 2,879,489 shares (+37.7%) to their portfolio in Q1 2025, for an estimated $196,640,303
MILLENNIUM MANAGEMENT LLC removed 2,729,426 shares (-88.7%) from their portfolio in Q1 2025, for an estimated $186,392,501
CAPITAL RESEARCH GLOBAL INVESTORS removed 2,335,053 shares (-16.2%) from their portfolio in Q1 2025, for an estimated $159,460,769
CITADEL ADVISORS LLC removed 2,134,018 shares (-50.1%) from their portfolio in Q1 2025, for an estimated $145,732,089
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ added 2,015,971 shares (+171.0%) to their portfolio in Q1 2025, for an estimated $137,670,659
JANUS HENDERSON GROUP PLC added 2,011,196 shares (+385.4%) to their portfolio in Q1 2025, for an estimated $137,344,574
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$DXCM Congressional Stock Trading
Members of Congress have traded $DXCM stock 7 times in the past 6 months. Of those trades, 3 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $DXCM stock by members of Congress over the last 6 months:
REPRESENTATIVE ROBERT BRESNAHAN has traded it 3 times. They made 2 purchases worth up to $30,000 on 05/15, 02/25 and 1 sale worth up to $15,000 on 04/08.
REPRESENTATIVE JEFFERSON SHREVE has traded it 3 times. They made 1 purchase worth up to $50,000 on 05/08 and 2 sales worth up to $100,000 on 05/12, 04/07.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$DXCM Analyst Ratings
Wall Street analysts have issued reports on $DXCM in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
Citigroup issued a "Buy" rating on 05/22/2025
Piper Sandler issued a "Overweight" rating on 05/02/2025
Wells Fargo issued a "Overweight" rating on 03/08/2025
Bernstein issued a "Outperform" rating on 01/08/2025
To track analyst ratings and price targets for $DXCM, check out Quiver Quantitative's $DXCM forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Insider Sale: EVP of $DXCM Sells 1,466 Shares

The S&P 500 Index ($SPX) (SPY) Tuesday closed up +1.11%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +1.19%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +1.53%. September E-mini S&P futures (ESU25) are up +1.11%, and September E-mini Nasdaq futures (NQU25) are up +1.52%.
Stock indexes rallied sharply on Tuesday, with the S&P 500 and Nasdaq 100 posting 4-month highs and the Dow Jones Industrials reaching a 3-1/2 month high. Global equity markets rallied, and WTI crude oil prices plunged more than -6%, after President Trump announced that Israel and Iran had agreed to a tentative ceasefire, spurring hopes for a lasting resolution to the conflict. The easing of geopolitical risks boosted market sentiment and prompted a risk-on for asset markets. Also, the plunge in crude prices reduced inflation expectations and knocked the 10-year T-note yield to a 1-1/2 month low.
Join 200K+ Subscribers: Find out why the midday Barchart Brief newsletter is a must-read for thousands daily.
Stocks rallied on Tuesday despite some negative economic news and hawkish Fed commentary. The Conference Board's June US consumer confidence index unexpectedly declined, and Fed Chair Powell, New York Fed President Williams, and Atlanta Fed President Bostic said they favored keeping interest rates on hold.
The US Apr S&P CoreLogic composite-20 home price index rose +3.42% y/y, weaker than expectations of +3.90% and the smallest increase in 1-3/4 years.
The Conference Board's June US consumer confidence index unexpectedly fell -5.4 to 93.0, weaker than expectations of an increase to 99.8.
The US June Richmond Fed manufacturing conditions survey unexpectedly rose +2 to -7, stronger than expectations of a decline to -10.
Fed Chair Powell said, "The effects of tariffs will depend, among other things, on their ultimate level, and for the time being, we are well-positioned to wait to learn more about the likely course of the economy before considering any adjustments to our policy stance."
New York Fed President Williams said it's "entirely appropriate" for the Fed to hold interest rates steady while they analyze the full impact of policy changes on the job market and inflation.
Atlanta Fed President Bostic said the Fed doesn't need to cut interest rates, with companies planning to raise prices later this year in response to higher import taxes and with the job market still stable.
The markets this week will look to see if the ceasefire between Israel and Iran holds. Also, any new tariff news or trade deals will be scrutinized. On Wednesday, Mr. Powell will testify before the Senate Banking Committee on monetary policy. Also, on Wednesday, US Mar new home sales are expected to fall -6.7% m/m to 693,000. On Thursday, Q1 GDP is expected to be unrevised at -0.2% (q/q annualized). Also, weekly initial unemployment claims are expected to be unchanged at 245,000. Friday brings May personal spending (expected +0.1% m/m) and May personal income (expected +0.3% m/m). Also, the May core PCE price index, the Fed's preferred price gauge, is expected to rise by +0.1% m/m and +2.6% y/y. Finally, the revised June University of Michigan US consumer sentiment index is expected to fall -0.2 to 60.3.
The markets are discounting the chances at 19% for a -25 bp rate cut at the July 29-30 FOMC meeting.
Overseas stock markets on Tuesday settled sharply higher. The Euro Stoxx 50 climbed to a 1-week high and closed up +1.44%. China's Shanghai Composite rose to a 3-month high and closed up +1.15%. Japan's Nikkei Stock 225 rallied to a 4-month high and closed up +1.14%.
Interest Rates
September 10-year T-notes (ZNU25) Tuesday closed up +6.5 ticks. The 10-year T-note yield fell -5.3 bp to 4.295%. Sep T-notes climbed toa 1-1/2 month high Tuesday, and the 10-year T-note yield fell to a 1-1/2 month low of 4.283%. T-notes recovered from early losses Tuesday and moved higher after a -6% plunge in WTI crude oil knocked inflation expectations lower and sparked short covering in T-notes. The 10-year breakeven inflation rate fell to a 1-week low of 2.286%. Additionally, an unexpected decline in the Conference Board's US June consumer confidence index was bullish for T-notes. T-notes added to their gains on comments from Fed Chair Powell, who said potential changes to the enhanced supplementary leverage ratio should encourage banks to hold more Treasuries.
T-notes initially moved lower on Tuesday as the announcement of a tentative ceasefire between Israel and Iran sparked a sharp rally in global equity markets, reducing safe-haven demand for T-notes. T-note prices were also undercut by hawkish comments from Fed Chair Powell, who signaled he is in no rush to cut interest rates. Tuesday's $69 billion Treasury auction of 2-year T-notes was met with subpar demand and was negative for T-note prices as the auction had a bid-to-cover ratio of 2.58, below the 10-auction average of 2.62.
European government bond yields on Tuesday were mixed. The 10-year German bund yield rose to a 1-week high of 2.573% and finished up +3.6 bp to 2.543%. The 10-year UK gilt yield fell to a 1-1/2 month low of 4.447% and finished down -2.0 bp to 4.473%.
The German Jun IFO business climate index rose +0.9 to a 13-month high of 88.4, stronger than expectations of 88.0.
ECB Governing Council member Villeroy de Galhau said. "If we look at the present assessment of markets so far, inflation expectations remain moderate. If that was confirmed, it could possibly lead in the next six months to further accommodation."
Swaps are discounting the chances at 8% for a -25 bp rate cut by the ECB at the July 24 policy meeting.
US Stock Movers
Chipmakers rallied on Tuesday to lift the broader market. Advanced Micro Devices (AMD) and Intel (INTC) closed up more than +6%, and Marvell Technology (MRVL) closed up more than +5%. Also, Micron Technology (MU), Applied Materials (AMAT), and Lam Research (LRCX) closed up more than +4%. In addition, NXP Semiconductors NV (NXPI), KLA Corp (KLAC), and Broadcom (AVGO) closed up more than +3%, and GlobalFoundries (GFS) and Microchip Technology (MCHP) closed up more than +2%.
Airline stocks and cruise line operators moved higher Tuesday after crude prices plunged more than -6% to a 1-1/2 week low on the announcement of a ceasefire in the Israel-Iran conflict. Carnival (CCL) closed up more than +6%, and Norwegian Cruise Line Holdings (NCLH) closed up more than +4%. Also, American Airlines Group (AAL) and Alaska Air Group (ALK) closed up more than +3%, and Delta Airlines (DAL) and Royal Caribbean Cruises Ltd (RCL) closed up more than 2%.
Dexcom (DXCM) closed up more than +9% to lead gainers in the Nasdaq 100 after Health and Human Service Secretary Kennedy said his department is launching "one of the largest HHS campaigns in history" to encourage the use of wearable health devices.
Upstart Holdings (UPST) closed up more than +8% after Piper Sandler assumed coverage of the stock with a recommendation of overweight and a price target of $75.
Uber Technologies (UBER) closed up more than +7% after beginning its driverless ride service in Atlanta.
Lyft (LYFT) closed up more than +5% after TD Cowen upgraded the stock to buy from hold with a price target of $21.
Mastercard (MA) closed up more than +2% after deepening its partnership with Fiserv to integrate its new FIUSD token across a range of Mastercard products and services.
Energy producers and energy service providers sold off on Tuesday after WTI crude oil sank by more than -6%. Occidental Petroleum (OXY) and Exxon Mobil (XOM) closed down more than -3%. Also, Chevron (CVX) closed down more than -2% to lead losers in the Dow Jones Industrials. In addition, ConocoPhillips (COP) and Hess Corp (HESS) closed down more than -2%. Finally, Devon Energy (DVN), Diamondback Energy (FANG), and Phillips 66 (PSX) closed down more than -1%.
Defense contractors retreated Tuesday with the announcement of a ceasefire in the Israel-Iran war. Northrop Grumman (NOC) closed down more than -3%. Also, RTX Corp (RTX), Lockheed Martin (LMT), Huntington Ingalls Industries (HII), and L3Harris Technologies (LHX) closed down more than -1%. In addition, General Dynamics (GD) closed down -0.45%.
Precious metals mining stocks were under pressure Tuesday, with the price of COMEX gold falling to a 2-week low. Anglogold Ashanti Plc (AU) closed down more than -4% and Gold Fields Ltd (GFI) closed down more than -3%. Also, Newmont (NEM) closed down more than -2%.
Advanced Auto Parts (AAP) closed down more than -7% to lead auto parts retailers lower after Goldman Sachs downgraded the stock to sell from neutral with a price target of $46. Also, AutoZone (AZO) closed down more than -3% to lead losers in the S&P 500, and O'Reilly Automotive (ORLY) closed down more than -2%.
Dollar General (DG) closed down more than -1% after Goldman Sachs downgraded the stock to neutral from buy.
Earnings Reports (6/25/2025)
Daktronics Inc (DAKT), General Mills Inc (GIS), HB Fuller Co (FUL), Jefferies Financial Group Inc (JEF), Micron Technology Inc (MU), MillerKnoll Inc (MLKN), Novagold Resources Inc (NG), Paychex Inc (PAYX), Steelcase Inc (SCS), Winnebago Industries Inc (WGO), Worthington Steel Inc (WS).
On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Stocks Soar as Middle East Tensions Ease and Bond Yields Fall

DexCom DXCM delivered robust first-quarter 2025 results, underpinned by strong category demand, record new patient growth and meaningful progress in its long-term strategic initiatives. As the year progresses, several key growth drivers are set to propel the business forward, even as the company faces operational and regulatory headwinds. Dexcom’s strong commercial execution, expanding access footprint and pipeline innovation position it well for long-term growth. Yet, execution in logistics, regulatory compliance, and payer strategy will be critical for converting these tailwinds into sustainable margin expansion.
This Zacks Rank #3 (Hold) company’s shares have gained 18.6% quarter to date compared to the industry’s 4.5% decline. The S&P 500 Index has improved 6.9% in the same time frame.
DXCM, a renowned medical device company and provider of continuous glucose monitoring (CGM) systems, has a market capitalization of $31.76 billion. It projects a 23.1% growth rate over the next five years and anticipates maintaining a strong performance going forward.
Image Source: Zacks Investment Research
DexCom’s earnings surpassed the Zacks Consensus Estimate in two of the trailing four quarters and missed twice, the average surprise being 0.47%.
Access Gain and Market Penetration
A major inflection point for Dexcom in 2025 is the significant expansion in reimbursement coverage for people with type 2 diabetes (T2D), particularly those who are not on insulin. As of summer 2025, Dexcom’s G7 continuous glucose monitor (CGM) will be covered by all three major pharmacy benefit managers (PBMs) for anyone with diabetes, unlocking access for nearly 6 million non-insulin users. Encouragingly, the first quarter already saw a material increase in new starts from this cohort, the highest in Dexcom’s history. Physician prescribing patterns are shifting in tandem with these policy changes, setting the stage for accelerating patient adoption in the back half of the year.
Simultaneously, Dexcom’s over-the-counter CGM, Stelo, is helping capture a broader audience, including patients with prediabetes and those interested in wellness and metabolic health. The company has rolled out app enhancements, launched on Amazon, and observed a rising subscription trend among early adopters. While still in early stages, Stelo adds a consumer-facing channel that complements the prescription-based G7 ecosystem.
Image Source: dexcom.com
Innovation and Commercial Execution
The upcoming launch of the 15-Day G7 system marks a technological leap for Dexcom. With improved accuracy (MARD of 8.0%) and extended wear time, the device is expected to bolster gross margins and deepen product differentiation. Integration efforts with insulin pump partners and payer contracting are already underway to ensure a seamless rollout in the second half of 2025.
Additionally, Dexcom continues to benefit from operational leverage. Following a major sales force expansion in 2024, the company is now optimizing reach and productivity, especially in the basal and primary care segments. Internationally, momentum is building in markets like France and Japan, aided by Dexcom ONE’s growing presence and type 2 coverage wins.
Dexcom’s $2.7 billion cash position and the announcement of a $750 million share buyback reflect strong balance sheet health and confidence in long-term cash flow generation. Despite inflation and logistics cost headwinds, the company reaffirmed its full-year revenue and EBITDA margin guidance, highlighting effective cost control and prioritization.
Estimate Trend
DexCom has witnessed a stable estimate revision trend for 2025. In the past 30 days, the Zacks Consensus Estimate for 2025 earnings per share has remained stable at $2.03.
Image Source: Zacks Investment Research
The consensus mark for the company’s second-quarter revenues is pegged at $1.12 billion, indicating an 11.8% improvement from the year-ago quarter’s reported number. The consensus estimate for earnings is pinned at 45 cents per share, implying an improvement of 4.7% year over year.
Image Source: Zacks Investment Research
Navigating Near-Term Challenges
However, Dexcom is not without headwinds. Gross margin guidance for fiscal 2025 was revised down to nearly 62%, primarily due to supply-chain disruptions that began in late 2024. To maintain customer continuity, Dexcom resorted to costly chartered flights and now faces a prolonged inventory rebuild. These freight-related expenses, combined with nearly 50 bps of inflation from raw material tariffs and FX volatility, are expected to weigh on profitability through the third quarter.
Separately, Dexcom is addressing a warning letter from the FDA tied to 2024 inspections. While it does not restrict product approvals or sales, it demands ongoing resource allocation and operational focus. The company is cooperating with the agency and has begun implementing corrective measures.
Lastly, while Dexcom is advocating Medicare coverage for non-insulin T2D users, progress hinges on a randomized controlled trial set to report results in late 2025 or early 2026. A favorable outcome could unlock another major addressable market.
DexCom, Inc. Price
DexCom, Inc. price | DexCom, Inc. Quote
CGM Competition on the Rise
While Dexcom leads in sensor accuracy and access, its three listed rivals — Abbott Laboratories ABT, Medtronic MDT and Senseonics SENS — are rapidly innovating, creating a more competitive and segmented CGM market landscape in 2025 and beyond.
Abbott Laboratories continues to expand its CGM footprint with its FreeStyle Libre family and the recent launch of Libre Rio, an FDA-cleared OTC device targeting insulin-free Type 2 diabetes patients. Abbott Laboratories’ broad portfolio and consumer wellness push with Lingo directly challenge Dexcom’s Stelo strategy, especially in the growing OTC and metabolic health market.
Medtronic, while spinning off its diabetes unit, remains a strong force through its MiniMed 780G system. Its integration of CGM with insulin pumps competes directly with Dexcom’s G7-enabled automated delivery partnerships. The forthcoming spin-off could streamline Medtronic’s focus and reinvigorate innovation.
Senseonics, although smaller in scale, presents a differentiated offering with its implantable Eversense CGM. With sensor wear times of up to 365 days, it appeals to a niche segment prioritizing convenience and minimal maintenance, pressuring Dexcom to enhance G7’s longevity and user comfort. As adoption grows, Senseonics’ Eversense could influence payer and clinician preference dynamics, particularly among high-adherence, low-maintenance patient cohorts.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Medtronic PLC (MDT) : Free Stock Analysis Report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
Senseonics Holdings, Inc. (SENS) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

DXCM's Access Gains and Operational Strength Offset Margin Pressures

NICHOLAS AUGUSTINOS, a director at $DXCM, sold 2,618 shares of the company on 06-13-2025 for an estimated $213,864. We received data on the trade from a recent SEC filing. This was a sale of approximately 6.6% of their shares of this class of stock. Following this trade, they now own 37,083 shares of this class of $DXCM stock.
$DXCM Insider Trading Activity
$DXCM insiders have traded $DXCM stock on the open market 18 times in the past 6 months. Of those trades, 0 have been purchases and 18 have been sales.
Here’s a breakdown of recent trading of $DXCM stock by insiders over the last 6 months:
KEVIN R SAYER (Chairman, CEO & President) has made 0 purchases and 2 sales selling 65,857 shares for an estimated $5,186,579.
MICHAEL JON BROWN (EVP, Chief Legal Officer) has made 0 purchases and 2 sales selling 23,000 shares for an estimated $1,757,790.
JEREME M SYLVAIN (EVP, Chief Financal Officer) has made 0 purchases and 5 sales selling 21,091 shares for an estimated $1,543,112.
SADIE STERN (EVP, Chief HR Officer) has made 0 purchases and 3 sales selling 19,453 shares for an estimated $1,494,797.
JACOB STEVEN LEACH (EVP, Chief Operating Officer) has made 0 purchases and 2 sales selling 16,710 shares for an estimated $1,219,602.
NICHOLAS AUGUSTINOS has made 0 purchases and 2 sales selling 6,290 shares for an estimated $517,906.
MATTHEW VINCENT DOLAN (EVP, Strategy & Corporate Dev) sold 1,183 shares for an estimated $102,819
BRIDGETTE P HELLER sold 352 shares for an estimated $24,756
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$DXCM Hedge Fund Activity
We have seen 480 institutional investors add shares of $DXCM stock to their portfolio, and 504 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 2,925,241 shares (+40.6%) to their portfolio in Q1 2025, for an estimated $199,764,707
JENNISON ASSOCIATES LLC added 2,879,489 shares (+37.7%) to their portfolio in Q1 2025, for an estimated $196,640,303
MILLENNIUM MANAGEMENT LLC removed 2,729,426 shares (-88.7%) from their portfolio in Q1 2025, for an estimated $186,392,501
CAPITAL RESEARCH GLOBAL INVESTORS removed 2,335,053 shares (-16.2%) from their portfolio in Q1 2025, for an estimated $159,460,769
CITADEL ADVISORS LLC removed 2,134,018 shares (-50.1%) from their portfolio in Q1 2025, for an estimated $145,732,089
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ added 2,015,971 shares (+171.0%) to their portfolio in Q1 2025, for an estimated $137,670,659
JANUS HENDERSON GROUP PLC added 2,011,196 shares (+385.4%) to their portfolio in Q1 2025, for an estimated $137,344,574
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$DXCM Congressional Stock Trading
Members of Congress have traded $DXCM stock 5 times in the past 6 months. Of those trades, 2 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $DXCM stock by members of Congress over the last 6 months:
REPRESENTATIVE ROBERT BRESNAHAN has traded it 3 times. They made 2 purchases worth up to $30,000 on 05/15, 02/25 and 1 sale worth up to $15,000 on 04/08.
REPRESENTATIVE JEFFERSON SHREVE sold up to $50,000 on 04/07.
REPRESENTATIVE KEVIN HERN sold up to $100,000 on 12/31.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$DXCM Analyst Ratings
Wall Street analysts have issued reports on $DXCM in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
Citigroup issued a "Buy" rating on 05/22/2025
Piper Sandler issued a "Overweight" rating on 05/02/2025
Wells Fargo issued a "Overweight" rating on 03/08/2025
Bernstein issued a "Outperform" rating on 01/08/2025
To track analyst ratings and price targets for $DXCM, check out Quiver Quantitative's $DXCM forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Insider Sale: Director at $DXCM Sells 2,618 Shares

The S&P 500 Index ($SPX) (SPY) Friday closed down -0.01%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +0.13%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.11%. June E-mini S&P futures (ESM25) are down -0.10%, and June E-mini Nasdaq futures (NQM25) are down -0.16%.
Stock indexes on Friday settled mixed. Stocks saw early pressure Friday as concern about US trade policy weighs on market sentiment. Late Thursday, US Treasury Secretary Bessent said that trade talks with China were "a bit stalled" and that a call between President Trump and Chinese President Xi Jinping may be needed to reach a deal. Stocks sank to their lows Friday when President Trump accused China of violating an agreement with the US to ease tariffs. US Trade Representative Greer said that China is "slow-walking" approvals for export licenses for rare-earth materials and is in noncompliance with the agreement both countries made earlier this month.
Join 200K+ Subscribers: Find out why the midday Barchart Brief newsletter is a must-read for thousands daily.
However, stock indexes recovered from early losses and traded mixed as short covering emerged Friday afternoon on hopes that trade tensions will ease with China after President Trump expressed confidence that the matter can be resolved when he said he'll "speak to President Xi and hopefully work it out." Also, Friday's decline in the 10-year T-note yield to a 3-week low was supportive for stocks.
US economic news on Friday was mainly supportive for stocks as Apr personal spending rose as expected and Apr personal income rose more than expected. Also, the Apr core PCE price index, the Fed's preferred inflation gauge, eased to its lowest level in more than 4 years, a dovish factor for Fed policy. In addition, US consumer sentiment was revised higher, and inflation expectations were revised lower.
US Apr personal spending rose +0.2% m/m, right on expectations. Apr personal income rose +0.8% m/m, stronger than expectations of +0.3% m/m and the biggest increase in 15 months.
The US Apr core PCE price index, the Fed's preferred inflation gauge, rose +0.1% m/m and +2.5% y/y, right on expectations. The +2.5% y/y report was the smallest year-on-year advance in more than 4 years.
The US May Chicago PMI unexpectedly fell -4.1 to 40.5, weaker than expectations of an increase to 45.0.
The University of Michigan US May consumer sentiment index was revised upward by +1.4 to 52.2, stronger than expectations of 51.5.
The University of Michigan US May 1-year inflation expectations indicator was revised lower to +6.6% from the previously reported +7.3%, weaker than expectations of +7.1%. Also, the May 5-10 year inflation expectations indicator was revised lower to +4.2%, weaker than expectations of no change at +4.6%.
Comments on Thursday evening from Dallas Fed President Logan signaled the Fed could keep interest rates unchanged in the medium term when she said it might be "quite some time" before Fed officials know how the economy will respond to tariffs and other policy changes and the Fed adjusts interest rates.
The markets are discounting the chances at 5% for a -25 bp rate cut at the next FOMC meeting on June 17-18.
Q1 earnings reporting season is winding down. So far, more than 90% of companies in the S&P 500 have reported quarterly results, and 77% have beaten estimates, the highest percentage since Q2 of 2024. Earnings growth in Q1 is running at +13.1%, compared with just +6.6% expected before the start of the season. Full-year 2025 corporate profits for the S&P 500 are seen rising +9.4%, down from the forecast of +12.5% in early January.
Overseas stock markets on Friday settled lower. The Euro Stoxx 50 closed down -0.08%. China's Shanghai Composite closed down -0.47%. Japan's Nikkei Stock 225 closed down -1.22%.
Interest Rates
June 10-year T-notes (ZNM25) Friday closed up +2.5 ticks. The 10-year T-note yield fell -0.8 bp to 4.420%. June T-notes on Friday climbed to a 3-week high and posted modest gains, and the 10-year T-note fell to a 3-week low of 4.385%. T-notes on Friday recovered from early losses and moved higher on the increase in safe-haven demand for government debt after US-China trade tensions escalated when President Trump accused China of violating the tariff agreement with the US. T-notes also have support after the US Apr core PCE price index, the Fed's preferred inflation gauge, posted its smallest year-on-year advance in more than four years, and after inflation expectations were revised lower, dovish factors for Fed policy.
Hawkish comments from Dallas Fed President Logan undercut T-note prices when she said it may be "quite some time" before the Fed adjusts interest rates. Also, concerns about rising wage pressures weighed on T-notes after Friday's news that US Apr personal income posted its largest increase in 15 months.
European government bond yields on Friday moved lower. The 10-year German bund yield fell to a 3-week low of 2.497% and finished down -0.8 bp at 2.500%. The 10-year UK gilt yield fell -0.2 bp to 4.647%.
Eurozone Apr M3 money supply rose +3.9% y/y, stronger than expectations of +3.7% y/y.
German Apr retail sales unexpectedly fell -1.1% m/m, weaker than expectations of a +0.2% m/m increase and the biggest decline in more than 1-1/2 years.
German May CPI (EU harmonized) rose +0.2% n/n and +2.1% y/y, stronger than expectations of +0.1% m/m and +2.0% y/y.
Swaps are discounting the chances at 98% for a -25 bp rate cut by the ECB at the June 5 policy meeting.
US Stock Movers
Ulta Beauty (ULTA) closed up more than +11% to lead gainers in the S&P 500 after reporting Q1 EPS of $6.70, well above the consensus of $5.80 and raised its 2026 EPS forecast to $22.65-$23.20 from a previous estimate of $22.50-$22.90, stronger than the consensus of $22.95.
Zscaler (ZS) closed up more than +9% to lead gainers in the Nasdaq 100 after reporting Q3 revenue of $678.0 million, better than the consensus of $666.3 million, and raising its full-year revenue forecast to $2.66 billion from a previous forecast of $2.64 billion-$2.65 billion, above the consensus of $2.65 billion.
Palantir Technologies (PLTR) closed up more than +7 after the New York Times reported that President Trump is expanding the use of the company's technology platform to the IRS, HHS, and DHS.
Unity Software (U) closed up more than +9% after Jeffries upgraded the stock to buy from hold with a price target of $29.
Costco Wholesale (COST) closed up more than +3% after reporting Q3 EPS of $4.28, better than the consensus of $4.24.
Nordson (NDSN) closed up more than +1% after Oppenheimer upgraded the stock to outperform from market perform with a price target of $260.
Dexcom (DXCM) closed up more than +1% after Goldman Sachs initiated coverage on the stock with a buy recommendation and a price target of $104.
Marvell Technology (MRVL) closed down more than -5% to lead chip stocks lower after forecasting Q2 adjusted gross margin of 59% to 60%, with the midpoint slightly below the consensus of 59.6%. Also, Lam Research (LRCX) closed down -4%, and GlobalFoundries (GFS) and Intel (INTC) closed down more than -3%. In addition, Micron Technology (MU), Nvidia (NVDA), Advanced Micro Devices (AMD), ARM Holdings Plc (ARM), NXP Semiconductors NV (NXPI), ON Semiconductor (ON), KLA Corp (KLAC), and Qualcomm (QCOM) closed down more than -2%.
Regeneron Pharmaceuticals (REGN) closed down more than -19% to lead losers in the S&P 500 and Nasdaq 100 after its itepekimab, an experimental drug jointly developed with Sanofi for chronic obstructive pulmonary disease, showed disappointing results in late-stage trial.
Cooper Cos (COO) closed down more than -14% after cutting its full-year organic growth forecast to 5%-6% from a previous forecast of 6%-8%.
The Gap (GAP) closed down more than -20% after forecasting Q2 net sales about flat y/y and warning of a $250 million to $300 million hit to earnings should tariffs remain at current levels of 30% for most goods from China and 10% for other countries.
Elastic NV (ESTC) closed down more than -12% after forecasting 2026 revenue of $1.66 billion to $1.67 billion, below the consensus of $1.68 billion.
Eastman Chemical (EMN) closed down more than -3% after the Trump administration canceled a $375 million award to the company for a molecular recycling project in Texas.
Earnings Reports (6/2/2025)
Credo Technology Group Holding (CRDO), Science Applications International Corp (SAIC), The Campbell's Company (CPB).
On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Stocks Settle Mixed on Trade Tensions and Positive Economic News

Fintel reports that on May 30, 2025, Goldman Sachs initiated coverage of DexCom (NasdaqGS:DXCM) with a Buy recommendation.
Analyst Price Forecast Suggests 19.19% Upside
As of May 6, 2025, the average one-year price target for DexCom is $101.15/share. The forecasts range from a low of $82.82 to a high of $120.75. The average price target represents an increase of 19.19% from its latest reported closing price of $84.86 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for DexCom is 4,731MM, an increase of 14.05%. The projected annual non-GAAP EPS is 1.98.
What is the Fund Sentiment?
There are 1,813 funds or institutions reporting positions in DexCom. This is an decrease of 76 owner(s) or 4.02% in the last quarter. Average portfolio weight of all funds dedicated to DXCM is 0.25%, an increase of 0.39%. Total shares owned by institutions increased in the last three months by 0.68% to 435,424K shares. The put/call ratio of DXCM is 0.85, indicating a bullish outlook.
What are Other Shareholders Doing?
Baillie Gifford holds 14,180K shares representing 3.62% ownership of the company. In its prior filing, the firm reported owning 14,613K shares , representing a decrease of 3.05%. The firm decreased its portfolio allocation in DXCM by 63.38% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 12,360K shares representing 3.15% ownership of the company. In its prior filing, the firm reported owning 12,259K shares , representing an increase of 0.81%. The firm decreased its portfolio allocation in DXCM by 7.65% over the last quarter.
Capital Research Global Investors holds 12,037K shares representing 3.07% ownership of the company. In its prior filing, the firm reported owning 14,372K shares , representing a decrease of 19.40%. The firm decreased its portfolio allocation in DXCM by 22.22% over the last quarter.
VFINX - Vanguard 500 Index Fund Investor Shares holds 10,858K shares representing 2.77% ownership of the company. In its prior filing, the firm reported owning 10,573K shares , representing an increase of 2.62%. The firm decreased its portfolio allocation in DXCM by 7.92% over the last quarter.
Jennison Associates holds 10,523K shares representing 2.68% ownership of the company. In its prior filing, the firm reported owning 7,644K shares , representing an increase of 27.36%. The firm decreased its portfolio allocation in DXCM by 25.84% over the last quarter.
Dexcom Background Information
(This description is provided by the company.)
DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Goldman Sachs Initiates Coverage of DexCom (DXCM) with Buy Recommendation

Below is Validea's guru fundamental report for DEXCOM INC (DXCM). Of the 22 guru strategies we follow, DXCM rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth.
DEXCOM INC (DXCM) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
BOOK/MARKET RATIO:
PASS
RETURN ON ASSETS:
PASS
CASH FLOW FROM OPERATIONS TO ASSETS:
PASS
CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS:
PASS
RETURN ON ASSETS VARIANCE:
PASS
SALES VARIANCE:
PASS
ADVERTISING TO ASSETS:
PASS
CAPITAL EXPENDITURES TO ASSETS:
FAIL
RESEARCH AND DEVELOPMENT TO ASSETS:
FAIL
Detailed Analysis of DEXCOM INC
DXCM Guru Analysis
DXCM Fundamental Analysis
More Information on Partha Mohanram
Partha Mohanram Portfolio
About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Sometimes research that changes the investing world can come from the halls of academia. Partha Mohanram is a great example of this. While academic research has shown that value investing works over time, it has found the opposite for growth investing. Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. His research paper "Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School.
Additional Research Links
Top Healthcare Stocks
Dividend Aristocrats 2025
Wide Moat Stocks
Recession Proof Stocks
High Insider Ownership Stocks
Factor-Based Stock Portfolios
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.